Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.

The product is licensed to Akom-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akom, Inc [NASDAQ: AKRX] and Strides Arcolab Ltd.

Fosphenytoin is the third approval amongst 22 sterile submissions the Company has submitted with US FDA.

Mr. Arun Kumar ? Vice Chairman and Group CEO of Strides Arcolab stated:

“We are excited with our third sterile injecatable approval and are delighted having achieved a key milestone in creating a global sterile injectable business.”